The Fresh York Times

July 23, 2017

The approval of gene therapy for leukemia, expected in the next few months, will open the door to a radically fresh class of cancer treatments.

Companies and universities are racing to develop these fresh therapies, which re-engineer and turbocharge millions of a patient’s own immune cells, turning them into cancer killers that researchers call a “living drug.” One of the big goals now is to get them to work for many other cancers, including those of the breast, guts, ovary, lung and pancreas. Continue reading Companies Rush to Develop ‘Utterly Transformative’ Gene Therapies